Rapid Screen for Genotoxicants, Chemoprotectors, and Radioprotectors
快速筛查基因毒物、化学保护剂和放射保护剂
基本信息
- 批准号:7107411
- 负责人:
- 金额:$ 13.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-05-01 至 2006-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): This research project addresses an important problem faced by the chemical and drug industries? their requirement to evaluate the DNA damaging potential of ever larger numbers of new chemical entities in shorter periods of time. This situation presents opportunities for small businesses that are able to provide solutions to these challenges. The work proposed herein addresses industry's need for higher throughput toxicity assessment through the development of an automated in vitro chromosomal damage assay. Chromosome damage will be quantified by flow cytometric micronucleus measurements. Importantly, the methodology that will be developed over the course of this project not only represents a high volume genotoxicant screening system, but also one that can be configured to identify agents which protect against chromosomal damage. This project addresses a stated need of investigators working to develop the next generation of biological response modifiers (BRMs). BRMs that provide chemo- or radio-protection hold great promise in several important arenas, including cancer treatments which are typically dose-limited by normal tissue responses. The identification and development of BRMs have other important applications, and include enhanced protection of our troops during times of war, and also for civilian victims of chemical or radiological terrorist attacks. The planned Phase 1 and Phase 2 efforts have thus been designed to provide a rapid and efficient assay for detecting the genotoxicant, radioprotectant, or chemoprotectant potential of test chemicals. This screening assay will help chemical and drug companies allocate their resources to the most promising candidates, eliminating hazardous entities early in development. Furthermore, by aiding in the identification of next generation BRMs, cancer patients and armed forces will benefit from the availability of chemo- and radio-protectant drugs.
描述(由申请人提供):该研究项目解决了化学和药物工业面临的一个重要问题?他们需要在更短的时间内评估越来越多的新化学实体的DNA损伤潜力。这种情况为能够为这些挑战提供解决方案的小企业提供了机会。本文提出的工作通过开发自动化体外染色体损伤测定来解决工业对更高通量毒性评估的需求。将通过流式细胞仪微核测量定量染色体损伤。重要的是,将在本项目过程中开发的方法不仅代表了高容量遗传毒性筛选系统,而且还可以配置为识别防止染色体损伤的药物。该项目致力于开发下一代生物反应调节剂(BRM)的研究人员的需求。提供化疗或放射保护的BRM在几个重要领域具有很大的前景,包括通常受正常组织反应剂量限制的癌症治疗。生物放射性物质的识别和开发还有其他重要的应用,包括在战争期间加强对我们部队的保护,以及保护化学或放射性恐怖袭击的平民受害者。因此,计划的I期和II期研究旨在提供一种快速有效的试验方法,用于检测供试化学品的遗传毒性、辐射防护或化学防护潜力。这种筛选分析将帮助化学和制药公司将其资源分配给最有前途的候选人,在开发早期消除危险实体。此外,通过帮助识别下一代BRM,癌症患者和武装部队将受益于化疗和放射保护药物的可用性。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEPHEN D DERTINGER其他文献
STEPHEN D DERTINGER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEPHEN D DERTINGER', 18)}}的其他基金
Versatile Mutation Assay Based on the Pig-A Locus
基于 Pig-A 基因座的多功能突变测定
- 批准号:
7692880 - 财政年份:2008
- 资助金额:
$ 13.33万 - 项目类别:
Versatile Mutation Assay Based on the Pig-A Locus
基于 Pig-A 基因座的多功能突变测定
- 批准号:
7611833 - 财政年份:2008
- 资助金额:
$ 13.33万 - 项目类别:
Rapid Screen for Genotoxicants, Chemoprotectors, and Radioprotectors
快速筛查基因毒物、化学保护剂和放射保护剂
- 批准号:
7502677 - 财政年份:2006
- 资助金额:
$ 13.33万 - 项目类别:
Rapid Screen for Genotoxicants, Chemoprotectors, and Radioprotectors
快速筛查基因毒物、化学保护剂和放射保护剂
- 批准号:
7404983 - 财政年份:2005
- 资助金额:
$ 13.33万 - 项目类别:
In vivo mutation assay based on pig-a locus
基于pig-a基因座的体内突变测定
- 批准号:
6841023 - 财政年份:2004
- 资助金额:
$ 13.33万 - 项目类别:
相似海外基金
XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies
XVIR-110 是一种超长效 INSTI,用于 IND 支持研究中的 HIV 暴露前预防
- 批准号:
10764186 - 财政年份:2023
- 资助金额:
$ 13.33万 - 项目类别:
Molecular dissection of extrachromosomal DNA formation, development, and evolution
染色体外 DNA 形成、发育和进化的分子解剖
- 批准号:
10640520 - 财政年份:2023
- 资助金额:
$ 13.33万 - 项目类别:
Genome Instability Induced Anti-Tumor Immune Responses
基因组不稳定性诱导的抗肿瘤免疫反应
- 批准号:
10626281 - 财政年份:2023
- 资助金额:
$ 13.33万 - 项目类别:
Project 1: Combining PARP inhibition with radiation to sensitize HR proficient pancreatic cancers to immunotherapy
项目 1:将 PARP 抑制与放射治疗相结合,使 HR 熟练的胰腺癌对免疫治疗敏感
- 批准号:
10554472 - 财政年份:2023
- 资助金额:
$ 13.33万 - 项目类别:
Cytosolic SINE retrotransposable element cDNA and mitochondrial DNA in aging retina
衰老视网膜中的胞质 SINE 逆转录转座元件 cDNA 和线粒体 DNA
- 批准号:
10722062 - 财政年份:2023
- 资助金额:
$ 13.33万 - 项目类别:
Dual targeting of cGAS-STING and splicing to prime lung cancer immunogenicity
cGAS-STING 和剪接的双重靶向以提高肺癌免疫原性
- 批准号:
10749760 - 财政年份:2023
- 资助金额:
$ 13.33万 - 项目类别:
Role of cGAS-STING in cardiomyocyte cell cycle regulation
cGAS-STING 在心肌细胞周期调节中的作用
- 批准号:
10625952 - 财政年份:2023
- 资助金额:
$ 13.33万 - 项目类别:
Exploiting markers of genomic instability in high-risk pre-invasive ovarian cancer
利用高风险浸润前卵巢癌基因组不稳定性标记
- 批准号:
10719535 - 财政年份:2023
- 资助金额:
$ 13.33万 - 项目类别:
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.
IND 促进 E1v1.11 的非临床开发,E1v1.11 是一种用于治疗脊髓性肌萎缩症的吗啉代反义寡核苷酸。
- 批准号:
10569744 - 财政年份:2023
- 资助金额:
$ 13.33万 - 项目类别:
Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation
Alpha 粒子结合 ATR 抑制激活免疫系统:机制和临床前转化
- 批准号:
10636348 - 财政年份:2023
- 资助金额:
$ 13.33万 - 项目类别: